Clinical Trial

Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)

Study acronym: CLIMBED
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Trial Details
NCT Number NCT07168876
Lead Sponsor Epiliquid Holding, Inc
Conditions Colorectal Cancer (CRC)
Enrollment 3,200 participants
Start Date 2024-04-04
Primary Completion 2025-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-11